- Page 1 and 2:
Guidelines forComplications ofCance
- Page 3:
Dedicated toAll our patients atThe
- Page 6 and 7:
Section IIHead & Neck 151Complicati
- Page 8 and 9:
PrefaceTreatment of cancer by vario
- Page 10:
Section — IGeneralContributorsDr.
- Page 13 and 14:
6. Complications after breast recon
- Page 15 and 16:
promises to reduce this risk of ser
- Page 17 and 18:
preceded by increased sensory hyper
- Page 19 and 20:
had significant lymphoedema. The fa
- Page 21 and 22:
2. Smoking as a risk factor for wou
- Page 23 and 24:
4. Preoperative core needle biopsy
- Page 25 and 26:
eduction mammoplasty, and axillary-
- Page 27 and 28:
postoperative wound infection follo
- Page 29 and 30:
ablative surgical treatment for car
- Page 31 and 32:
postoperative seroma formation usin
- Page 33 and 34:
dressing consisted of a circumferen
- Page 35 and 36:
mastectomies with axillary node cle
- Page 37 and 38:
mastectomy for breast cancer. Early
- Page 39 and 40:
monitored for the development of po
- Page 41 and 42:
modality, and tumor stage distribut
- Page 43 and 44:
26. Pain and other symptoms during
- Page 45 and 46:
28. Coping, catastrophizing and chr
- Page 47 and 48:
surgical technique at the time of m
- Page 49 and 50:
0.001), 0.315 cm +/- 1.27 at the an
- Page 51 and 52:
or heat and superficial incision is
- Page 53 and 54:
RecommendationsA. Preparation of th
- Page 55 and 56:
3. Mangram AJ, Horan TC, Pearson ML
- Page 57 and 58:
Mild hypothermia increases blood lo
- Page 59 and 60:
Perioperative Normothermia to Reduc
- Page 61 and 62:
Priorities: Restoration of circulat
- Page 63 and 64:
than 1.5 times control values but f
- Page 65 and 66:
outcomes that may result from the u
- Page 67 and 68:
Preoperative Preparation of the Pat
- Page 69 and 70:
patients, or other patients who may
- Page 71 and 72:
Obstruction can occur at the level
- Page 74 and 75:
c. Administer face mask preoxygenat
- Page 76 and 77:
5. The use of exhaled carbon dioxid
- Page 78 and 79:
disorder) may occur after an episod
- Page 80 and 81:
undergoing general anesthesia, eith
- Page 82 and 83:
anesthesia awareness occurred in ea
- Page 84 and 85:
The current guidelines are actually
- Page 86 and 87:
o S - Strong Recommendation -Commit
- Page 88 and 89:
oSource control ASAP after successf
- Page 90 and 91:
oooWean steroids once vasopressors
- Page 92 and 93:
Mechanical ventilation of sepsis-in
- Page 94 and 95:
o CVVH offers easier management inh
- Page 96 and 97:
critically ill patient that are con
- Page 98 and 99:
Rivers E, Nguyen B, Havstad S, et a
- Page 100 and 101:
in survival of 7.6%. By the second
- Page 102 and 103:
parameters (gastric mucosal Pco2, s
- Page 104 and 105:
syndrome. We therefore conducted a
- Page 106 and 107:
Complications After Limb SalvageSur
- Page 108 and 109:
local tumor and to preserve as much
- Page 110 and 111:
femoral head to the center of the k
- Page 112 and 113:
4. Griffin AM, Parsons JA, Davis AM
- Page 114 and 115:
20. Roberts P, Chan D, Grimer RJ, e
- Page 116 and 117:
An infection can have disastrous co
- Page 118 and 119:
and facilitating reimplantation sur
- Page 120 and 121:
features of a two-stage revision is
- Page 122 and 123:
patients had an amputation. Two oth
- Page 124 and 125:
its main role is confined to ruling
- Page 126 and 127:
2. Capanna R, Morris HG, Campanacci
- Page 128 and 129:
21. Wilson MG, Kelley K, Thornhill
- Page 130 and 131:
39. Love C, Marwin SE, Tomas MB, Kr
- Page 132 and 133:
5. A systematic review of 25 RCT’
- Page 134 and 135:
(cefazolin or cefuroxime) or penici
- Page 136 and 137:
should be based on the isolates fro
- Page 138 and 139:
such as concomitant use of prophyla
- Page 140 and 141:
Surgical techniqueAdherence to meti
- Page 142 and 143:
2. Another small prospective random
- Page 144 and 145:
Antibiotic prophylaxis for dental a
- Page 146 and 147:
Antimicrobial Prophylaxis in Orthop
- Page 148 and 149:
35. Tai CC, Nirvani AA, Holmes A, e
- Page 150 and 151:
53. Parker MJ, Roberts C. Closed su
- Page 152 and 153:
Vessel Related Issues in Sarcoma:Ev
- Page 154 and 155:
sequences may be of value. They cau
- Page 156 and 157:
an excellent alternative to amputat
- Page 158:
5. Hünerbein M, Hohenberger P, Str
- Page 162 and 163:
Oral IncompetenceOral competence is
- Page 164 and 165:
flap is insensate and has no motor
- Page 166 and 167:
16. R. Song, Y. Gao, Y. Song, Y. Yu
- Page 168 and 169:
The incidence is usually lower afte
- Page 170 and 171:
Late fibrotic phase: Attempted tiss
- Page 172 and 173:
Ref: A Lyons, N Ghazali/ British J
- Page 174 and 175:
17. Store G, Boysen M. Mandibular o
- Page 176 and 177:
amino acids, proteins and traces of
- Page 178 and 179:
RTOG, EORTC and CTCAE, version 3 fo
- Page 180 and 181:
difference in the disease related p
- Page 182 and 183:
References1. Bourhis J, Rosine D. R
- Page 184 and 185:
with head and neck cancer. N Engl J
- Page 186 and 187:
MucositisMucositis is an inflammato
- Page 188 and 189:
Type of cancer: high risk for mucos
- Page 190 and 191:
Oral care protocol1. Brush all toot
- Page 192 and 193:
3. El-Sayed S, Nabid A, ShelleyW, e
- Page 194 and 195:
1) Recipient site problems- The maj
- Page 196 and 197:
estoration of vascular flow to tiss
- Page 198 and 199:
General Complications- Deep vein th
- Page 200 and 201:
Nerve Injuries(Recurrent and Superi
- Page 202 and 203:
paramedian position, it will result
- Page 204 and 205:
along with its variations, and a me
- Page 206 and 207:
anatomy as related to surgery of th
- Page 208 and 209:
Risk factorsCentral compartment (Le
- Page 210 and 211:
Goal - To raise serum calcium level
- Page 212 and 213:
Pharyngocutaneous Fistula (PC Fistu
- Page 214 and 215:
Based on our institutional practice
- Page 216 and 217:
fistula: The Memorial University ex
- Page 218 and 219:
Risk factors (LOE-5)Patient factors
- Page 220 and 221:
oCircumferencial excision and inser
- Page 222 and 223:
y trauma or tumor, exposing the und
- Page 224 and 225:
Arytenoid cartilage is reported to
- Page 226 and 227:
Filntisis, G.A., et al. “Laryngea
- Page 228 and 229:
As high as 52% patients are detecte
- Page 230 and 231:
ManagementPostural exercisesDisorde
- Page 232 and 233:
References1) Objective assessment o
- Page 234 and 235:
Diagnosis Average time to hypothyro
- Page 236 and 237:
Management of Facial Nerve InjuryIn
- Page 238 and 239:
2. Interposition or cable graft (to
- Page 240 and 241:
Prevention of corneal exposure Tars
- Page 242 and 243:
flushing) and localized sweating (g
- Page 244 and 245:
Other options :1. Intracutaneous in
- Page 246 and 247:
Shoulder Dysfunction or PainfulShou
- Page 248 and 249:
EMG studies on scapulo-humeral and
- Page 250 and 251:
Chyle Fistula after Neck Dissection
- Page 252 and 253:
Rationale:LCTs, which constitute 70
- Page 254 and 255:
CSF Leak after Craniofacial Resecti
- Page 256 and 257:
to the muscle to recreate the orbit
- Page 258 and 259:
Conservative treatmentIt is logical
- Page 260 and 261:
Complications Associated with use o
- Page 262 and 263:
Following is the example of hematol
- Page 264 and 265:
ooooooo direct interaction with the
- Page 266 and 267:
ooooointravenously over 15 minutes
- Page 268 and 269:
in most of the patients. The common
- Page 270:
Section — IIIRadiotherapyContribu
- Page 273 and 274:
nodes are involved or suspected to
- Page 275 and 276:
function. In general, with conventi
- Page 277 and 278:
like ultrasonography, CT scan, endo
- Page 279 and 280:
catheter passed through the anus in
- Page 281 and 282:
Acute symptoms usually subside seve
- Page 283 and 284:
granulocytopenia, thrombocytopenia
- Page 285 and 286:
adiation therapy), IMRT (intensity-
- Page 287 and 288:
patients who have received radical
- Page 289 and 290:
ate expected in the standard popula
- Page 292 and 293:
adjusting for competing causes of d
- Page 294 and 295:
therapy (3D-CRT) and intensity modu
- Page 296 and 297:
attributed to use of cisplatin base
- Page 298 and 299:
Conclusion:Incidence of SMN is incr
- Page 300 and 301:
11. Travis LB, Fossa SD, Schonfeld
- Page 302 and 303:
adiation-related solid SMNs will in
- Page 304 and 305:
0.71, p
- Page 306 and 307:
5.65%) within 45 years after a CNS
- Page 308 and 309:
adiation damage though supporting v
- Page 310 and 311:
without calcification. Inflammation
- Page 312 and 313:
patients treated using the original
- Page 314 and 315:
incidence of valvular thickening at
- Page 316 and 317:
12. Hancock S, Hoppe R. Long-term c
- Page 318 and 319:
syndrome and bronchiolitis oblitera
- Page 320 and 321:
Darby SC, McGale P, Taylor CW, Peto
- Page 322 and 323:
undertaken, based on individual pat
- Page 324 and 325:
Pathophysiological Aspects:The func
- Page 326 and 327:
Symptoms: Symptoms related to pulmo
- Page 328 and 329: Prevention of Pneumonitis and Lung
- Page 330 and 331: genotyping analysis of single nucle
- Page 332 and 333: Registry of Patients. We computed I
- Page 334 and 335: eceived elective nodal irradiation
- Page 336 and 337: Int J Radiat Oncol Biol Phys. 1995
- Page 338 and 339: worsening during the treatment shou
- Page 340 and 341: Differential Diagnosis: This sign i
- Page 342 and 343: Dose Incidence Comments Author>30 G
- Page 344 and 345: PET scan findings have been describ
- Page 346 and 347: 3. Pallis CA, Louis S, Morgan RL.:
- Page 348 and 349: 24. Abbatucci JS, Delozier T, Quint
- Page 350 and 351: and summarized into specific recomm
- Page 352 and 353: adequate. With the increasing use o
- Page 354 and 355: Complications are mainly described
- Page 356 and 357: IQ decline is associated with sever
- Page 358 and 359: activity’ of a person, essentiall
- Page 360 and 361: development after brain tumor thera
- Page 362 and 363: Highest relative risk of second can
- Page 364 and 365: Suggested Reading:A) Neuropsycholog
- Page 366 and 367: aseline. Male sex, longer symptomat
- Page 368 and 369: number of patients. Cognition was p
- Page 370 and 371: 16 years, the corresponding value w
- Page 372 and 373: 15 of 20 (75%) subjects, endocrine
- Page 374 and 375: OBJECTIVE: To assess cerebrovascula
- Page 376 and 377: hypometabolism. Of the 17 patients
- Page 380: Section — IVMedical OncologyContr
- Page 383 and 384: Initial investigations - Complete b
- Page 385 and 386: In low risk group, patient may rece
- Page 387 and 388: trial design issues.1 Fluconazole s
- Page 389 and 390: Duration of treatment may depend up
- Page 391 and 392: Antibacterial agents-Overall risk E
- Page 393 and 394: Gram positive DOSE Spectrum Comment
- Page 395 and 396: Broad spectrum DOSE Spectrum Commen
- Page 397 and 398: Broad spectrum DOSE Spectrum Commen
- Page 399 and 400: Broad spectrum DOSE Spectrum Commen
- Page 401 and 402: 6. Bow EJ, Rotstein C, Noskin GA, e
- Page 403 and 404: 2. Delayed CINV: Nausea and vomitin
- Page 405 and 406: Recommended Treatment OptionsAcute
- Page 407 and 408: Evidence Based Management Guideline
- Page 409 and 410: Management of refractory and breakt
- Page 411 and 412: serotonin antagonist and dexamethas
- Page 413 and 414: (no vomiting and no use of rescue t
- Page 415 and 416: within 24 hours after the start of
- Page 417 and 418: with age, often becoming clinically
- Page 419 and 420: guidelines for screening & manageme
- Page 421 and 422: Level Treatment Method of Frequency
- Page 423 and 424: 15. Wallace WH, Blacklay A, Eiser C
- Page 425 and 426: health status domains were assessed
- Page 427 and 428: of childhood cancer survivors is no
- Page 429 and 430:
Tumor Lysis SyndromeDefinition: Tum
- Page 431 and 432:
the grade of CTLS is defined by the
- Page 433 and 434:
Alkalinization for patients who wil
- Page 435 and 436:
deficiency should include a thoroug
- Page 437 and 438:
icarbonate and calcium should not b
- Page 439 and 440:
and should have ready access to ras
- Page 441 and 442:
Table 3 Risk Factors for Tumor Lysi
- Page 443 and 444:
Table 5 Recommended Rasburicase Dos
- Page 445 and 446:
1. Guidelines for the management of
- Page 447 and 448:
3. A randomized comparison between
- Page 449 and 450:
acid levels (6.4-16.8 mg/dl; median
- Page 451 and 452:
adiographic pattern is the hilar ly
- Page 453 and 454:
study involving 105 patients was 8.
- Page 455 and 456:
10. Sostman HD, Matthay RA, Putman
- Page 457 and 458:
distinguish between a normal GFR an
- Page 459 and 460:
of methotrexate induced nephropathy
- Page 461 and 462:
Bibliography1. De Jonge MJ, Verweij
- Page 463 and 464:
Mucositis and GastrointestinalToxic
- Page 465 and 466:
pathogenesis is similar for gastroi
- Page 467 and 468:
acceptable oral protocol include re
- Page 469 and 470:
Treatment of gastrointestinal mucos
- Page 471 and 472:
Hepatotoxicity ofChemotherapeutic A
- Page 473 and 474:
Capecitabine is the prodrug for 5-F
- Page 475 and 476:
Topotecan causes elevation of trans
- Page 477 and 478:
Daunorubicin: Reduce dose by 25% if
- Page 479 and 480:
9. Spriggs DR, Stopa E, Mayer RJ, e
- Page 481 and 482:
Dermatologic Toxicity of Antineopla
- Page 483 and 484:
ecause 15% of scalp hairs are not i
- Page 485 and 486:
5. Batchelor D. Hair and cancer che
- Page 487 and 488:
Anemia and Cancer - incidence, etio
- Page 489 and 490:
most accurate method for detecting
- Page 491 and 492:
levels, to define anemia and this m
- Page 493 and 494:
Darbopoietin Vs Epoetin Alfa: Is Th
- Page 495 and 496:
arm (2.4 g/dl) compared to patients
- Page 497 and 498:
12. Yellen SB, Cella DF, Webster K,
- Page 499 and 500:
490NOTES
- Page 501:
NOTES